Holen Sie sich die Stockscreener-App
145.72
2.07%
-3.08
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
BlackRock Inc. Makes New Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
248,322 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Eagle Health Investments LP - MarketBeat
Great Lakes Advisors LLC Invests $6.97 Million in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $178 - Moomoo
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 12-Month High on Analyst Upgrade - MarketBeat
PTGX Maintained by BMO Capital -- Price Target Raised to $178 - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, BMO Capital Markets Analyst Says - MarketBeat
Johnson & Johnson Invests $300.22 Billion in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity - ChartMill
Protagonist Therapeutics stock hits all-time high at 155.01 USD By Investing.com - Investing.com Australia
Protagonist Therapeutics stock hits all-time high at 155.01 USD - Investing.com
Farallon group (PTGX) discloses 6.43M-share, warrant‑backed stake in Protagonist - Stock Titan
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance
Protagonist Therapeutics CEO Dinesh Patel sells $14.9m in stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics CEO Dinesh Patel sells $14.9m in stock - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $5,085,176.28 in Stock - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 65,761 Shares - MarketBeat
Protagonist Therapeutics (PTGX) CEO sells 100,000 shares after option exercise - Stock Titan
(PTGX) Risk Channels and Responsive Allocation - Stock Traders Daily
Protagonist Therapeutics gains FDA nod for ICOT... - Pluang
Protagonist Therapeutics: 'Strong Buy' ICOTYDE FDA Approval And PN-881 Advancement (PTGX) - Seeking Alpha
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year HighHere's Why - MarketBeat
Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says - Yahoo Finance
PTGX (PTGX) insider files to sell 225,000 shares under Rule 144 - stocktitan.net
PTGX Maintained by Truist Securities -- Price Target Raised to $170 - GuruFocus
PTGX Looks 105.7% Overvalued on GF Value™ - GuruFocus
PTGX Maintained by Wedbush -- Price Target Raised to $173 - GuruFocus
Protagonist upgraded at Goldman Sachs on potential of autoimmune asset - seekingalpha.com
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $170 - moomoo.com
PROTAGONIST THERAPEUTICS, INC. : WEDBUSH RAISES TARGET PRICE TO $173 FROM $118 - Bitget
Wedbush Adjusts PT on Protagonist Therapeutics to $173 From $118, Keeps Outperform Rating - Moomoo
PTGX Upgraded by Goldman Sachs -- Price Target Raised to $186 - GuruFocus
Truist Adjusts Price Target on Protagonist Therapeutics to $170 From $145, Maintains Buy Rating - marketscreener.com
Goldman Sachs upgrades Protagonist Therapeutics stock rating on drug potential - Investing.com Australia
Goldman Sachs Upgrades Protagonist Therapeutics to Buy From Neutral, Adjusts PT to $186 From $110 - marketscreener.com
HC Wainwright Has Negative Forecast for PTGX FY2026 Earnings - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Rating Lowered to Buy at Wall Street Zen - MarketBeat
Protagonist Therapeutics, Inc. Just Recorded A 21% EPS Beat: Here's What Analysts Are Forecasting Next - 富途牛牛
Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock - Yahoo Finance
Protagonist Therapeutics (PTGX): State Street discloses 5.2% beneficial ownership stake - Stock Titan
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $153 to $175 - moomoo.com
HC Wainwright Has Negative Forecast for PTGX Q3 Earnings - MarketBeat
PTGX Maintained by Citigroup -- Price Target Raised to $175 - GuruFocus
Bank of America Corp DE Has $136.54 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics stock hits all-time high at 143.43 USD By Investing.com - Investing.com UK
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $152.14, Implies 11% Upside - TradingView
Citigroup Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock - marketbeat.com
Protagonist Therapeutics stock hits all-time high at 143.43 USD - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 12-Month High Following Strong Earnings - marketbeat.com
Protagonist Therapeutics2026 Funding Rounds & List of Investors - Tracxn
PROTAGONIST THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $167 FROM $117 - Bitget
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by California State Teachers Retirement System - MarketBeat
PTGX SWOT Analysis: Strong Pipeline and Strategic Collaborations Highlighted in 10-Q Filing - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates - Yahoo Finance
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Protagonist Therapeutics, Inc 2026: Revenue $213.48M, EPS $2.29— 10-Q Summary - TradingView
Protagonist Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q2 Revenue $213.5M, Vs. FactSet Est of $199.8M - Moomoo
Protagonist Therapeutics (NASDAQ: PTGX) jumps on $269.8M 2026 collaboration revenue - Stock Titan
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):